Answers are grounded in this paper and cite their sources.
Thyroid cancer (THCA) is the most common endocrine malignancy associated with clinical challenges like recurrence, aggressive variants, and therapy resistance. This study employed an integrative systems-biology approach to interrogate The Cancer Genome Atlas (TCGA)-THCA transcriptomic data to identify candidate genes and drug–target relationships for THCA. Differentially expressed genes (DEGs) were identified and used to construct protein–protein interaction and gene regulatory network (GRN) as well as generate topological, clustering, and enrichment analyses. Candidate genes were interrogated using survival analysis, genetic alteration, correlation, immune infiltration, drug–gene interaction, and molecular docking. Findings were independently validated in two Gene Expression Omnibus (GEO) cohorts. A total of 424 DEGs (191 up-regulated, 233 down-regulated) were identified. Seven candidate genes, DPP4, GABRB2, HMGA2, SERPINA1, ADH1B, KLHDC8A , and DLG2 , were prioritized, and enrichment analyses revealed functional associations with extracellular matrix remodeling, MAPK signaling, cell-junction regulation, and synaptic signaling. These candidate genes displayed immune infiltration disparities and differential expression in independent GEO datasets. Docking simulations predicted favorable binding geometries for Sitagliptin- DPP4 and Flumazenil- GABRB2 , while 100-ns molecular dynamics simulations further authenticated the binding affinities of these two complexes. In conclusion, we identified independent candidate genes and in-silico prioritized drug–target interactions for further preclinical investigations of THCA.
No takes yet. Share an insight, caveat, or question.
Zohrabzadeh et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: